RecruitingNot ApplicableNCT04883463

Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury


Sponsor

University of California, Los Angeles

Enrollment

12 participants

Start Date

Sep 27, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This is a phase 1 study of safety and feasibility of cervical spinal cord stimulator implantation in cervical SCI subjects who are ventilator dependent. The Investigators will be focusing on the safety and feasibility of this approach. Participants may qualify for the study if they are male or female 18-75 years old, are at least 1 year after original injury, have injury at C2 to C7 level, and dependent on mechanical ventilation to help them breathe. Additionally, they need to be able to attend up to twice weekly testing sessions for up to 21 months.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria8

  • Male or female 18-75 years
  • At least 1 year from initial cervical spinal cord injury
  • Non-progressive Spinal Cord Injury (SCI) at C2 - C7 (non-conus injury)
  • Motor Complete ASIA Impairment Scale (A, B, or C)
  • Severe respiratory function compromise requiring dependency on invasive or noninvasive ventilation
  • Able to attend weekly testing sessions for up to 21 months.
  • Have intact chest/lung, upper and lower extremity anatomy. The neuromuscular connections between the spinal cord and its effector muscles (respiratory and extremity) are required to be intact
  • Have intact cognitive ability, able to follow commands/voice concerns, and give consent

Exclusion Criteria12

  • History of severe autonomic dysreflexia
  • Phrenic nerve or diaphragm pacer
  • Phrenic nerve paralysis
  • Musculoskeletal dysfunction, unhealed fracture, pressure ulcer of grade 3 and above in the European Pressure Ulcer Advisory Panel Grading System, active infection
  • Clinically significant depression or ongoing drug abuse as documented in the medical record
  • Received lung surgery within one year prior to study enrollment or has active intrinsic lung disease (e.g. COPD, acute or chronic lung infection, moderate to severe asthma, emphysema, cystic fibrosis, etc.)
  • Cardiopulmonary disease that precludes training or rehabilitation
  • Other implanted stimulation devices
  • Pregnant
  • Severe cardiac disease (e.g. heart failure, atherosclerosis, arrhythmia, stroke, etc.)
  • Subjects involved in other clinical trials not associated with this trial
  • Botox injections in respiratory associated muscles within the last 3 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEpidural stimulation

Epidural electrical stimulation implant weekly sessions for 21 months.


Locations(2)

Semel Institute of Neuroscience at UCLA

Los Angeles, California, United States

UCLA Clinical and Translational Research Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04883463


Related Trials